Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02467387 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure
A Phase 2 study of Non-Ischemic Heart Failure, sponsored by CardioCell.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 5
- Study locations
NCT02467387 is a Phase 2 study of Non-Ischemic Heart Failure that has completed, run by CardioCell. The registered enrollment target is 23 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT02467387, a Phase 2 study of Non-Ischemic Heart Failure, has completed, sponsored by CardioCell.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 5
- Study locations
Study Summary
A phase IIa study to assess the safety and preliminary efficacy of intravenous dose of ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells in subjects with non-ischemic heart failure.
Conditions Studied
Interventions
- DRUG Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
- DRUG Lactated Ringer's Solution
Study Locations (5)
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
Georgia
- Emory University Hospital - Atlanta
Illinois
- Northwestern University Centers for Heart Failure Therapy - Chicago
New York
- Stony Brook Heart Institute - Stony Brook
Pennsylvania
- Hospital of the University of Pennsylvania, Heart Failure and Transplant Program - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-06-01 |
| Est. Completion | 2017-05-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02467387
The ClinicalTrials.gov registry entry for NCT02467387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CardioCell, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Ischemic Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) is the first listed.
NCT02467387 reports 5 study locations spanning 5 distinct geographic areas - top geographies include District of Columbia, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT02467387 about?
NCT02467387 is a clinical study titled "A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure". A phase IIa study to assess the safety and preliminary efficacy of intravenous dose of ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells in subjects with non-ischemic heart failure.
What is the current status of trial NCT02467387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2014-06-01. Estimated completion is 2017-05-11.
What conditions does trial NCT02467387 study?
This clinical trial studies the following conditions: Non-Ischemic Heart Failure.
What interventions are being tested in trial NCT02467387?
The interventions under investigation include: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) (DRUG), Lactated Ringer's Solution (DRUG).
Who is sponsoring clinical trial NCT02467387?
This trial is sponsored by CardioCell, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02467387 being conducted?
This trial has 5 study locations across District of Columbia, Georgia, Illinois, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.